Mitigation of human-pathogenic fungi that exhibit resistance to medical agents: Can clinical antifungal stewardship help?

Future Microbiology

Volumn 9, Issue 3, 2014, Pages 307-325

  Hull, Claire M ^a   Purdy, Nicola J ^a   Moody, Suzy C ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

agriculture; antifungal stewardship; Aspergillus; environmental; resistance; selection

Indexed keywords

ALLYLAMINE DERIVATIVE; ANTIFUNGAL AGENT; ECHINOCANDIN; GRISEOFULVIN; HOST FACTOR; PESTICIDE; POLYENE ANTIBIOTIC AGENT; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; THYMIDYLATE SYNTHASE INHIBITOR; XENOBIOTIC AGENT;

ANTIFUNGAL RESISTANCE; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; DISEASE CARRIER; DISEASE SURVEILLANCE; ENZYME INACTIVATION; FITNESS; FUNGAL LIFE CYCLE STAGE; FUNGAL VIRULENCE; FUNGICIDAL ACTIVITY; HOST; HUMAN; LONGEVITY; MOLECULAR EPIDEMIOLOGY; MOULD; MULTIDRUG RESISTANCE; NONHUMAN; PATIENT MONITORING; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SEXUALITY; SURVIVAL; WASTE; YEAST; DRUG EFFECTS; FUNGUS; HOST PATHOGEN INTERACTION; MICROBIOLOGY; MYCOSES; PHYSIOLOGY; RISK FACTOR;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; ENVIRONMENTAL MICROBIOLOGY; FUNGI; HOST-PATHOGEN INTERACTIONS; HUMANS; MYCOSES; RISK FACTORS;

EID: 84899539829     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.160     Document Type: Review

References (107)

1. Neu HC. The crisis in antibiotic resistance. Science 257(5073), 1064-1073 (1992
2. Goff DA. Antimicrobial stewardship: Bridging the gap between quality care and cost. Curr. Opin. Infect. Dis. 24, S11-S20 (2011
3. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: A persistent public health problem. Clin. Microbiol. Rev. 20(1), 133-163 (2007
4. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: Report from the SENTRY Antimicrobial Surveillance Program (2008-2009). Diagn. Microbiol. Infect. Dis. 68(3), 278-283 (2010
5. Denning DW, Perlin DS. Azole resistance in Aspergillus: A growing public health menace. Future Microbiol. 6(11), 1229-1232 (2011
6. Edwards MR, Bartlett NW, Hussell T, Openshaw P, Johnston SL. The microbiology of asthma. Nat. Rev. Microbiol. 10(7), 459-471 (2012
7. Perfect JR. The triple threat of cryptococcosis: It.s the body site, the strain, and/or the host. MBio 3(4), e00165-12 (2012
8. Moellering RC Jr, Graybill JR Jr, McGowan JE, Corey L. Antimicrobial resistance prevention initiative-An update: Proceedings of an expert panel on resistance. Am. J. Infect. Control 35(9), S1-S23 (2007
9. Valerio M, Rodriguez C, Munoz P, Sanjurjo M. Antifungal use evaluation: A first step towards the design of antifungal stewardship. Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 51, M-283 (2011
10. Sinko J, Bryan J. Latest trends in fungal epidemiology inform treatment choices and stewardship initiatives. Future Microbiol. 7(10), 1141-1146 (2012
11. Ananda-Rajah MR, Slavin MA, Thursky KT. The case for antifungal stewardship. Curr. Opin. Infect. Dis. 25(1), 107-115 (2012
12. Lopez-Medrano F, Lizasoain M, Catalan M et al. A non-compulsory programme for management of antifungals in a university affiliated hospital: First report of an antifungal-stewardship program. Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 49, 367-367 (2009
13. Mondain V, Lieutier F, Hasseine L et al. A 6-year antifungal stewardship programme in a teaching hospital. Infection 41(3), 621-628 (2013
14. Hof H. Will resistance in fungi emerge on a scale similar to that seen in bacteria? Eur. J. Clin. Microbiol. Infect. Dis. 27(5), 327-334 (2008
15. Hof H. Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-Term application of azole antifungals in medicine? Drug Resist. Updates 11(1-2), 25-31 (2008
16. Hof H. Resistance of fungi against medically relevant antifungals. Andrias 19, 273 (2012
17. Pfaller MA. Antifungal drug resistance: Mechanisms, epidemiology, and consequences for treatment. Am. J. Med. 125(1), S3-S13 (2012
18. Vandeputte P, Ferrari S, Coste AT. Antifungal resistance and new strategies to control fungal infections. Int. J. Microbiol. 2012, 713687 (2012
19. European Centre for Disease Prevention and Control. Risk assessment on the impact of environmental usage of triazoles on the development and spread of resistance to medical triazoles in Aspergillus species. ECDC, Stockholm, Sweden (2013
20. Cornely OA, Aversa F, Cook P et al. Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy. Eur. J. Haematol. 87(4), 289-301 (2011
21. Denning DW, Bowyer P. Voriconazole resistance in Aspergillus fumigatus: Should we be concerned? Clin. Infect. Dis. 57(4), 521-523 (2013
22. Loyse A, Thangaraj H, Easterbrook P et al. Cryptococcal meningitis: Improving access to essential antifungal medicines in resource-poor countries. Lancet Infect. Dis. 13(7), 629-637 (2013
23. Chakrabarti A, Singh R. The emerging epidemiology of mould infections in developing countries. Curr. Opin. Infect. Dis. 24(6), 521-526 (2011
24. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin. Infect. Dis. 54, S23-S34 (2012
25. Kontoyiannis DP, Lewis RE, Lotholary O et al. Future directions in mucormycosis Research. Clin. Infect. Dis. 54, S79-S85 (2012
26. Martel CM, Parker JE, Bader O et al. Identification and characterization of four azole-resistant erg3 mutants of Candida albicans. Antimicrob. Agents Chemother. 54(11), 4527-4533 (2010
27. Martel CM, Parker JE, Bader O et al. A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14a-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B. Antimicrob. Agents Chemother. 54(9), 3578-3583 (2010
28. Morio F, Loge C, Besse B, Hennequin C, Le Pape P. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: New substitutions and a review of the literature. Diagn. Microbiol. Infect. Dis. 66(4), 373-384 (2010
29. Hull CM, Parker JE, Bader O et al. Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B. Antimicrob. Agents Chemother. 56(8), 4223-4232 (2012
30. Hull CM, Bader O, Parker JE et al. Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2. Antimicrob. Agents Chemother. 56(12), 6417-6421 (2012
31. Vandeputte P, Tronchin G, Larcher G et al. A nonsense mutation in the ERG6 gene leads to reduced susceptibility to polyenes in a clinical isolate of Candida glabrata. Antimicrob. Agents Chemother. 52(10), 3701-3709 (2008
32. Eddouzi J, Parker JE, Vale-Silva LA et al. Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals. Antimicrob. Agents Chemother. 57(7), 3182-3193 (2013
33. Chapeland-Leclerc F, Hennequin C, Papon N et al. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob. Agents Chemother. 54(3), 1360-1362 (2010
34. Healey KR, Katiyar SK, Raj S, Edlind TD. CRS-MIS in Candida glabrata: Sphingolipids modulate echinocandin-Fks interaction. Mol. Microbiol. 86(2), 303-313 (2012
35. Alexander BD, Johnson MD, Pfeiffer CD et al. Increasing echinocandin resistance in Candida glabrata: Clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56(12), 1724-1732 (2013
36. Kelly SL, Lamb DC, Taylor M, Corran AJ, Baldwin BC, Powderly WG. Resistance to amphotericin B associated with defective sterol delta(8-7) isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol. Lett. 122(1-2), 39-42 (1994
37. Hochenfellner F, Guelfand L, Cordoba S et al. Ergosterol content decrease in serial clonally-related isolates of recurrent cryptococcal meningitis, tolerant to amphotericin B (AMB). Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 41, 360 (2001
38. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TA. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. Aids 23(4), 525-530 (2009
39. Brun S, Dalle F, Saulnier P et al. Biological consequences of petite mutations in Candida glabrata. J. Antimicrob. Chemother. 56(2), 307-314 (2005
40. Tsai HF, Bard M, Izumikawa K et al. Candida glabrata erg1 mutant with increased sensitivity to azoles and to low oxygen tension. Antimicrob. Agents Chemother. 48(7), 2483-2489 (2004
41. Morio F, Pagniez F, Lacroix C, Miegeville M, Le Pape P. Amino acid substitutions in the Candida albicans sterol delta(5,6)-desaturase (Erg3p) confer azole resistance: Characterization of two novel mutants with impaired virulence. J. Antimicrob. Chemother. 67(9), 2131-2138 (2012
42. Vale-Silva LA, Coste AT, Ischer F et al. Azole resistance by loss of function of the sterol delta(5,6)-desaturase gene (ERG3) in Candida albicans does not necessarily decrease virulence. Antimicrob. Agents Chemother. 56(4), 1960-1968 (2012
43. Watson PF, Rose ME, Ellis SW, England H, Kelly SL. Defective sterol C5-6 desaturation and azole resistance-A new hypothesis for the mode of action of azole antifungals. Biochem. Biophys. Res. Commun. 164(3), 1170-1175 (1989
44. Guan XL, Souza CM, Pichler H et al. Functional interactions between sphingolipids and sterols in biological membranes regulating cell physiology. Mol. Biol. Cell 20(7), 2083-2095 (2009
45. Valachovic M, Bareither BM, Bhuiyan MS et al. Cumulative mutations affecting sterol biosynthesis in the yeast Saccharomyces cerevisiae result in synthetic lethality that is suppressed by alterations in sphingolipid profiles. Genetics 173(4), 1893-1908 (2006
46. Shahi P, Moye-Rowley WS. Coordinate control of lipid composition and drug transport activities is required for normal multidrug resistance in fungi. Biochim. Biophys. Acta 1794(5), 852-859 (2009
47. Ferrari S, Ischer F, Calabrese D et al. Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. PLoS Pathog. 5(1) (2009
48. Vale-Silva L, Ischer F, Leibundgut-Landmann S, Sanglard D. Gain-of-function mutations in PDR1, a regulator of antifungal drug resistance in Candida glabrata, control adherence to host cells. Infect. Immun. 81(5), 1709-1720 (2013
49. Arendrup MC, Mavridou E, Mortensen KL et al. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS ONE 5(4), e10080 (2010
50. Hull CM, Purdy NJ Nonantifungal clinical drug interventions and human-commensal fungi: What are we selecting? Future Microbiol. 8(7), 813-816 (2013
51. Lin XR, Hull CM, Heitman J. Sexual reproduction between partners of the same mating type in Cryptococcus neoformans. Nature 434(7036), 1017-1021 (2005
52. Alby K, Schaefer D, Bennett RJ. Homothallic and heterothallic mating in the opportunistic pathogen Candida albicans. Nature 460(7257), 890-U127 (2009
53. Arabatzis M, Velegraki A. Sexual reproduction in the opportunistic human pathogen Aspergillus terreus. Mycologia 105(1), 71-79 (2013
54. Swilaiman SS, O.Gorman CM, Balajee SA, Dyer PS. Discovery of a sexual cycle in Aspergillus lentulus, a close relative of A. fumigatus. Eukaryotic Cell 12(7), 962-969 (2013
55. O.Gorman CM, Fuller HT, Dyer PS. Discovery of a sexual cycle in the opportunistic fungal pathogen Aspergillus fumigatus. Nature 457(7228), 471-474 (2009
56. Coelho MA, Gonçalves C, Sampaio JP, Gonçalves P. Extensive intra-kingdom horizontal gene transfer converging on a fungal fructose transporter gene. PLoS Genet. 9(6), e1003587 (2013
57. Mansfield BE, Oltean HN, Oliver BG et al. Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi. PLoS Pathog. 6(9), e1001126 (2010
58. Asha S, Vidyavathi M. Cunninghamella-A microbial model for drug metabolism studies. A review. Biotechnol. Adv. 27(1), 16-29 (2009
59. Butts A, DiDone L, Koselny K et al. A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. Eukaryotic Cell 12(2), 278-287 (2013
60. Roemer T, Boone C. Systems-level antimicrobial drug and drug synergy discovery. Nat. Chem. Biol. 9(4), 222-231 (2013
61. Cools HJ, Hammond-Kosack KE. Exploitation of genomics in fungicide research: Current status and future perspectives. Mol. Plant Pathol. 14(2), 197-210 (2013
62. Camps SMT, van Der Linden JW, Li Y et al. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: A case study and review of the literature. Antimicrob. Agents Chemother. 56(1), 10-16 (2012
63. Snelders E, van Der Lee HAL, Kuijpers J et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5(11), 1629-1637 (2008
64. Snelders E, Veld R, Rijs A et al. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl. Environ. Microbiol. 75, 4053-4057 (2009
65. Verweij PE, Snelders E, Kema GHJ, Mellado E, Melchers WJG. Azole resistance in Aspergillus fumigatus: A side-effect of environmental fungicide use? Lancet Infect. Dis. 9(12), 789-795 (2009
66. Snelders E, Camps SM, Karawajczyk A et al. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS ONE 7(3), e31801 (2012
67. Verweij PE, van De Sande-Bruisma N, Kema GHJ, Melchers WJG. Azole resistance in Aspergillus fumigatus in The Netherlands-increase due to environmental fungicides? Ned. Tijdschr. Geneeskd. 156(25), A4458 (2012
68. Bader O, Weig M, Reichard U et al. Cyp51A-based mechanisms of Aspergillus fumigatus azole drug resistance present in clinical samples from Germany. Antimicrob. Agents Chemother. 57(8), 3513-3517 (2013
69. Camps SM, Rijs AJ, Klaassen CH et al. Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism. J. Clin. Microbiol. 50(8), 2674-2680 (2012
70. Chowdhary A, Kathuria S, Xu J et al. Clonal expansion and emergence of environmental multiple-Triazole-resistant Aspergillus fumigatus strains carrying the TR34/L98H mutations in the cyp51A gene in India. PLoS ONE 7(12), e52871 (2012
71. Escribano P, Pelaez T, Munoz P, Bouza E, Guinea J. Is azole resistance in Aspergillus fumigatus a problem in Spain? Antimicrob. Agents Chemother. 57(6), 2815-2820 (2013
72. Morio F, Aubin GG, Danner-Boucher I et al. High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis. J. Antimicrob. Chemother. 67(8), 1870-1873 (2012
73. Rath PM, Buchheidt D, Spiess B, Arfanis E, Buer J, Steinmann J. First reported case of azole-resistant Aspergillus fumigatus due to the TR/L98H mutation in Germany. Antimicrob. Agents Chemother. 56(11), 6060-6061 (2012
74. Seyedmousavi S, Hashemi SJ, Zibafar E et al. Azole-resistant Aspergillus fumigatus, Iran. Emerg. Infect. Dis. 19(5), 832-834 (2013
75. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob. Agents Chemother. 55(9), 4465-4468 (2011
76. van Der Linden JW, Camps SM, Kampinga GA et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin. Infect. Dis. 57(4), 513-520 (2013
77. Stammler G, Carstensen M, Koch A et al. Frequency of different CYP51-haplotypes of Mycosphaerella graminicola and their impact on epoxiconazole-sensitivity and-field efficacy. Crop Protect. 27, 1448-1456 (2008
78. Snelders E, Karawajczyk A, Verhoeven RJ et al. The structure-function relationship of the Aspergillus fumigatuscyp51A L98H conversion by site-directed mutagenesis: The mechanism of L98H azole resistance. Fungal Genet. Biol. 48(11), 1062-1070 (2011
79. Cross EW, Park S, Perlin DS. Cross-resistance of clinical isolates of Candida albicans and Candida glabrata to over-The-counter azoles used in the treatment of vaginitis. Microb. Drug Resist. 6(2), 155-161 (2000
80. Gnanadhas DP, Marathe SA, Chakravortty D. Biocides-resistance, cross-resistance mechanisms and assessment. Expert Opin. Invest. Drugs 22(2), 191-206 (2013
81. Sharma P, Kumar M, Mathur N, Singh A, Bhatnagar P, Sogani M. Health care industries: Potential generators of genotoxic waste. Environ. Sci. Pollut. Res. 20(8), 5160-5167 (2013
82. Liu X. Asian Mycological Congress and the 13th International Marine and Freshwater Mycology Symposia. Beijing, China, 19-24 August 2013
83. Etienne KA, Gillece J, Hilsabeck R et al. Whole genome sequence typing to investigate the Apophysomyces outbreak following a tornado in Joplin, Missouri, 2011. PLoS ONE 7(11), e49989 (2012
84. Fanfair RN, Benedict K, Bos J et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N. Engl. J. Med. 367(23), 2214-2225 (2012
85. Roy M, Benedict K, Deak E et al. A large community outbreak of blastomycosis in Wisconsin with geographic and ethnic clustering. Clin. Infect. Dis. 57(5), 655-662 (2013
86. Denning DW, Park S, Lass-Florl C et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin. Infect. Dis. 52(9), 1123-1129 (2011
87. Panackal AA, Li H, Kontoyiannis DP et al. Geoclimatic influences on invasive Aspergillosis after hematopoietic stem cell transplantation. Clin. Infect. Dis. 50(12), 1588-1597 (2010
88. Brilhante RS, Paiva MA, Sampaio CM et al. Yeasts from Macrobrachium amazonicum: A focus on antifungal susceptibility and virulence factors of Candida spp. FEMS Microbiol. Ecol. 76(2), 268-277 (2011
89. Castelo-Branco DS, Brilhante RS, Paiva MA et al. Azole-resistant Candida albicans from a wild Brazilian porcupine (Coendou prehensilis): A sign of an environmental imbalance? Med. Mycol. 51(5), 555-560 (2013
90. Brilhante RS, De Alencar LP, Cordeiro Rde A et al. Detection of Candida species resistant to azoles in the microbiota of rheas (Rhea americana): Possible implications for human and animal health. J. Med. Microbiol. 62, 889-895 (2013
91. Freeman R, Moore LS, Alvarez LG, Charlett A, Holmes A. Advances in electronic surveillance for healthcare-Associated infections in the 21st century: A systematic review. J. Hosp. Infect. 84(2), 106-119 (2013
92. Harris MR, Coote PJ. Combination of caspofungin or anidulafungin with antimicrobial peptides results in potent synergistic killing of Candida albicans and Candida glabrata in vitro. Int. J. Antimicrob. Agents 35(4), 347-356 (2010
93. Day JN, Chau TT, Wolbers M et al. Combination antifungal therapy for cryptococcal meningitis. N. Engl. J. Med. 368(14), 1291-1302 (2013
94. Loyse A, Bicanic T, Jarvis JN. Combination antifungal therapy for cryptococcal meningitis. N. Engl. J. Med. 368(26), 2522-2522 (2013
95. Hill JA, Ammar R, Torti D, Nislow C, Cowen LE. Genetic and genomic architecture of the evolution of resistance to antifungal drug combinations. PLoS Genet. 9(4), e1003390 (2013
96. Mehra T, Koeberle M, Braunsdorf C, Mailaender-Sanchez D, Borelli C, Schaller M. Alternative approaches to antifungal therapies. Exp. Dermatol. 21(10), 778-782 (2012
97. Groll AH, Lumb J. New developments in invasive fungal disease. Future Microbiol. 7(2), 179-184 (2012
98. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. (ICAAC). Chicago, IL, USA, 17-20 September 2011
99. Cassone A, Casadevall A. Recent progress in vaccines against fungal diseases. Curr. Opin. Microbiol. 15(4), 427-433 (2012
100. Pikman R, Ben-Ami R. Immune modulators as adjuncts for the prevention and treatment of invasive fungal infections. Immunotherapy 4(12), 1869-1882 (2012
101. Lin TY, Chin CR, Everitt AR et al. Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction. Cell Rep. 5(4), 895-908 (2013
102. De Hoog GS, Haase G, Chaturvedi V, Walsh TJ, Meyer W, Lackner M. Taxonomy of medically important fungi in the molecular era. Lancet Infect. Dis. 13(5), 385-386 (2013
103. Nuwaysir EF, Bittner M, Trent J, Barrett JC, Afshari CA. Microarrays and toxicology: The advent of toxicogenomics. Mol. Carcinog. 24(3), 153-159 (1999
104. Yasokawa D, Iwahashi H. Toxicogenomics using yeast DNA microarrays. J. Biosci. Bioeng. 110(5), 511-522 (2010
105. Snape JR, Maund SJ, Pickford DB, Hutchinson TH. Ecotoxicogenomics: The challenge of integrating genomics into aquatic and terrestrial ecotoxicology. Aquat. Toxicol. 67(2), 143-154 (2004
106. Fungal Research Trust. http://fungalresearchtrust.org/ howcommonarefungaldiseases2.pdf
107. Fungal Genome Initiative (FGI), Broad Institute. www.broadinstitute.org/ scientific-community/science/projects/fungal-genome-initiative/ fungal-genome-initiative.